VRNA - Verona Pharma PLC ADR

https://www.veronapharma.com

Momentum: Bearish

Recent News

All You Need to Know About Verona Pharma ( VRNA ) Rating Upgrade to Buy

Zacks Commentary • 1 month ago • score: 0.37

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Verona Pharma plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company is headquartered in London, the United Kingdom.

52W High

$106.44

52W Low

$25.79

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.14

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

35.09

EV/EBITDA (<8 favorable)

-20.89

EV/Revenue (<3 favorable)

40.61

P/S (TTM) (<3 favorable)

40.75

P/B (<3 favorable)

33.04

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.89%

Institutions (25–75% balanced)

95.01%

Shares Outstanding

84,979,000

Float

564,820,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

221,673,000

Gross Profit (TTM)

210,928,000

EPS (TTM)

-1.04

Profit Margin (>10% good)

-0.37%

Operating Margin (TTM) (higher better)

0.13%

ROE (TTM) (>15% strong)

-0.36%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.7886

0.8231

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025